AUROBINDO PHARMA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,152 INR | +1.81% |
|
+7.02% | +6.25% |
| Sales 2024 * | 287B 3.44B 274B | Sales 2025 * | 314B 3.77B 300B | Capitalization | 675B 8.09B 645B |
|---|---|---|---|---|---|
| Net income 2024 * | 31.44B 377M 30.03B | Net income 2025 * | 37.86B 454M 36.17B | EV / Sales 2024 * | 2.29 x |
| Net cash position 2024 * | 18.34B 220M 17.52B | Net cash position 2025 * | 35.81B 429M 34.21B | EV / Sales 2025 * | 2.03 x |
| P/E ratio 2024 * |
21.2
x | P/E ratio 2025 * |
17.4
x | Employees | 23,451 |
| Yield 2024 * |
0.36% | Yield 2025 * |
0.44% | Free-Float | 47.93% |
More Fundamentals
* Assessed data
More news
Latest transcript on Aurobindo Pharma
More recommendations
More press releases
More news
| 1 day | +1.81% | ||
| 1 week | +7.02% | ||
| Current month | +5.79% | ||
| 1 month | +3.45% | ||
| 3 months | -0.78% | ||
| 6 months | +33.72% | ||
| Current year | +6.25% |
1 week
1 077.05
1 156.45
1 month
1 069.301 156.45
Current year
958.501 177.10
1 year
581.251 177.10
3 years
397.201 177.10
5 years
288.851 177.10
10 years
278.531 177.10
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 66 | 25/12/86 | |
| Director of Finance/CFO | - | 31/12/12 | |
B. Adi Reddy
CMP | Compliance Officer | - | 31/05/16 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | 66 | 25/12/86 | |
| Founder | 66 | 25/12/86 | |
| Director/Board Member | 64 | 26/05/03 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.32% | 6 M€ | +6.07% | - | |
| 0.22% | 18 M€ | +4.71% | ||
| 0.12% | 11 M€ | +2.69% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/04/24 | 1,152 | +1.81% | 2 471 250 |
| 26/04/24 | 1,131 | +2.53% | 1,511,617 |
| 25/04/24 | 1,103 | +1.78% | 1,642,872 |
| 24/04/24 | 1,084 | -0.84% | 923,839 |
| 23/04/24 | 1,093 | +1.58% | 1,150,312 |
Delayed Quote NSE India S.E., April 29, 2024 at 12:40 pm
More quotes
Aurobindo Pharma specializes in the research, development, manufacturing and marketing of active pharmaceutical ingredients and generic pharmaceuticals. The group's activity is organized around 2 product families :
- generic drugs: for the treatment of neurological, cardiovascular, viral, gastroenterological, ophthalmologic and chronic diseases;
- active pharmaceutical ingredients.
At the end of March 2018, the group operated 23 production sites in India (19), the United States (3) and Brazil.
Net sales are distributed geographically as follows: India (12%), the United States (46.5%), Europe (31.2%) and other (10.3%).
Sector
Pharmaceuticals
Calendar
29/05/2024
- Q4 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
1,131
INR
Average target price
1,190
INR
Spread / Average Target
+5.23%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +6.25% | 7.95B | |
| +25.66% | 661B | |
| +26.74% | 566B | |
| -6.59% | 352B | |
| +19.50% | 332B | |
| +3.70% | 283B | |
| +13.43% | 231B | |
| +4.71% | 200B | |
| -9.53% | 195B | |
| -4.90% | 145B |
- Stock Market
- Equities
- AUROPHARMA Stock
